Skip to main content

Table 2 Baseline demographics and characteristics in immunocompromised children

From: Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program

Characteristic

Type of immune-compromising condition, n (%)

All

(n = 263)

Primary

immunodeficiencya

(n = 13)

Oncologic immunodeficiencyb

(n = 152)

Solid organ

transplantc

(n = 36)

Hematopoietic cell transplantd

(n = 17)

Othere

(n = 45)

Age, years

 Mean (SD)

6.4 (4.6)

7.8 (5.3)

6.0 (4.4)

7.2 (4.4)

5.9 (3.7)

6.8 (5.6)

 Median (range)

6 (0–17)

6 (0.83–17)

5 (0.25–17)

6 (0.5–16)

6 (1–14)

7 (0–17)

Sex

 Female

125 (48)

4 (21)

78 (51)

15 (42)

6 (35)

22 (49)

 Male

138 (52)

9 (69)

74 (49)

21 (58)

11 (65)

23 (51)

Race

 White

163 (62)

8 (62)

91 (60)

26 (72)

10 (59)

28 (62)

 Hispanic/Latino

47 (18)

0

34 (22)

5 (14)

3 (18)

5 (11)

 Black/African American

32 (12)

4 (31)

18 (12)

2 (6)

2 (12)

6 (13)

 Asian

5 (2)

0

3 (2)

0

0

2 (4)

 American Indian/Alaskan native

2 (1)

0

1 (1)

0

1 (6)

0

Unknown/Not reported

14 (5)

1 (8)

5 (3)

3 (8)

1 (6)

4 (9)

Location of VZV exposure

 Household

87 (33)

8 (62)

41 (27)

17 (47)

8 (47)

13 (29)

 Healthcare setting

102 (39)

2 (15)

75 (49)

8 (22)

5 (29)

13 (29)

 School/daycare/playgroup

55 (21)

1 (8)

25 (16)

11 (31)

2 (12)

16 (36)

 Otherf

12 (5)

2 (15)

8 (5)

0

1 (6)

1 (2)

 Unknown

6 (2)

0

3 (2)

0

1 (6)

2 (4)

Type of VZV exposure

 Varicella

190 (72)

9 (69)

109 (72)

30 (83)

10 (59)

32 (71)

 Herpes zoster

41 (16)

1 (8)

24 (16)

5 (14)

4 (24)

7 (16)

 Unknown/not specifiedg

32 (12)

3 (23)

19 (13)

1 (3)

3 (18)

6 (13)

Timing of VARIZIG administration

  < 96 h after exposure

237 (90)

11 (85)

136 (89)

34 (94)

16 (94)

40 (89)

 5–10 days after exposure

25 (10)

2 (15)

15 (10)

2 (6)

1 (6)

5 (11)

 Unknown

1 (0.4)

0

1 (1)

0

0

0

  1. Some characteristics may not total 100% because of rounding
  2. aIncludes participants with primary immunodeficiencies (cell-mediated immune deficiency [n = 1], combined immunodeficiency [n = 2], DiGeorge syndrome [n = 2], HIV infection/AIDS [n = 2], immunodeficiency common variable [n = 3], neutropenia [n = 1], tumor necrosis factor receptor–associated periodic syndrome [n = 1], and Wiskott-Aldrich syndrome [n = 1])
  3. bIncludes participants with oncologic conditions
  4. cIncludes participants who have undergone SOT and are taking anti-rejection medication
  5. dIncludes participants who have undergone HCT
  6. eIncludes participants with other immunocompromising conditions (adrenoleukodystrophy [n = 1], aplastic anemia [n = 3], anemia [n = 2], aplasia pure red cell [n = 1], arthritis [n = 1], asthma [n = 2], cardiac operation [n = 1], chronic granulomatous disease [n = 1], Cushingoid [n = 1], Evan’s syndrome [n = 1], focal segmental glomerulosclerosis [n = 1], Goodpasture’s syndrome [n = 1], Henoch-Schönlein purpura nephritis [n = 1], hypoplastic left heart syndrome [n = 1], juvenile-onset arthritis [n = 4], McKusick-Kaufman syndrome [n = 1], lupus nephritis [n = 1], nephrotic syndrome [n = 4], ornithine transcarbamylase deficiency [n = 1], polyarteritis nodosa [n = 1], premature baby [n = 7], sarcoidosis [n = 1], thrombocytopenia [n = 1], ulcerative colitis [n = 1], uveitis [n = 1], velocardiofacial syndrome [n = 1], and unknown/unspecified [n = 3])
  7. fOther locations of exposure included camp or sporting events
  8. gParticipants had known VZV exposure but type of VZV (either varicella zoster or herpes zoster) was not specified or known
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us